Mr. George Reznik reports

LIGHT AI ANNOUNCES NEW DIRECTOR APPOINTMENTS

Light AI Inc. has appointed two new directors to its board of directors, Robert Cartagena and Mario Vetro.

Mr. Cartagena is co-founder and managing partner of Mill Street Equity Partners LLC (formerly Mill Street Partners LLC), a specialty investment strategy development firm focused on middle-market dental and medical device companies. Mr. Cartagena had a 33-year career as a C-level executive and or board member for various dental manufacturing companies including Discus Dental LLC and DenMat Holdings LLC, serving as chief operating officer for each firm. At both companies Mr. Cartagena led the development and launch of products which are now household brands in the dental industry in product categories such as surgical lasers, dental materials, professional teeth whitening, magnification and more. He has created tremendous value at various companies through new product development, sales and marketing, as well as buy-side and sell-side M&A (merger and acquisition) in both private and public environments.

Mario Vetro brings substantial expertise in structuring and raising capital for growth companies with a focus on technology and the natural resources sector. He currently serves as chief executive officer of Commodity Partners Inc., a boutique merchant bank and advisory firm. There, he played a pivotal role in the co-founding of K92 Mining Inc., a company listed on the Toronto Stock Exchange, leading to the establishment of a world-class gold discovery and mining operation in Papua New Guinea. Building upon this success, Mr. Vetro excels at assembling formidable leadership teams, securing equity capital and devising strong business strategies.

The company also announces the Hugh Cleland is transitioning from the company's board of directors due to health reasons. Mr. Cleland has been instrumental in the company's transition to a public company and supporting the company in its financing and investor relations initiatives.

"Light AI is excited to welcome Robert Cartagena and Mario Vetro to its board of directors who bring extensive experience from their respective industries," stated Steven Semmelmayer, Light AI chair of the board of directors. "Mr. Cartagena's executive leadership roles building and operating global medical technology companies over the past 30 years will be instrumental in supporting the company's transition from research and development to commercialization while Mr. Vetro brings significant capital markets and corporate finance experience to support the company in this manner. I would like to thank Mr. Cleland for his efforts in supporting the company during his tenure as a director."

About Light AI Inc.

Light AI is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smart phone images -- starting with images of Strep A and anticipated expansion with COVID-19 along with other medical conditions -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind -- its hardware platform is the 4.5 billion smart phones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving health care delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA (Food and Drug Administration) validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57-per-cent accuracy rate and attained a negative predictive value of 100 per cent, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.